Fulgent Genetics Inc
FLGT
Get informed when a big investor buys or sells
+ FollowMarket Cap$470.03M
Close$
$7.40
60.1% downside
Current Fair Value
60.1% downsideOvervalued by 60.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $470.03 Million |
|---|---|
| Enterprise Value | $583.58 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.97 |
| Beta | 0.89 |
| Outstanding Shares | 28,005,000 |
Return
| Return on Equity | -8.42% |
|---|---|
| Return on Assets | -7.75% |
| Return on Invested Capital | -9.99% |
Valuation & Multiples
| P/E Ratio | -5.87 |
|---|---|
| PEG | -10.52 |
| Price to Sales | 1.69 |
| Price to Book Ratio | 0.53 |
| Enterprise Value to Revenue | 1.8 |
| Enterprise Value to EBIT | -5.74 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.24 |
| Debt to Equity | 0.14 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 31, 2026
EPS Estimate
$-0.46
Average shareholder expectationRevenue Estimate
$94.00 M
Average shareholder expectationNext Earnings Call
Expected Date
August 7, 2026
EPS Estimate
$-0.26
Average shareholder expectationRevenue Estimate
$89.95 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 41.54% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.83%▼ 54.87% |
|---|---|
| Total Invested | $11.60M▼ 95.82% |
| Investors Holding | 30▼ 131.00% |
ESG Score
No data
About Fulgent Genetics Inc
429 employees
CEO: Ming Hsieh Fulgent Genetics' proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy and...